The 20 references in paper L. Shpagina A., I. Shpagin S., O. Kotova S., T. Pospelova I., O. Gerasimenko N., Л. Шпагина А., И. Шпагин С., О. Котова С., Т. Поспелова И., О. Герасименко Н. (2017) “Дифференцированная терапия различных фенотипов хронической обструктивной болезни легких // Treatment of different phenotypes of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2016:i:6:p:681-693

1
Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких [Электронный ресурс].http://www.pulmonology.ru/publications/guide.php (дата обращения: 20.07.2016).
(check this in PDF content)
2
Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2016). Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.2016. Accessed July 20, 2016.
(check this in PDF content)
3
Kornmann O., Dahl R., Centanni S. et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur. Respir. J.2011; 37 (2): 273– 279. DOI: 10.1183/09031936.00045810.
(check this in PDF content)
4
Marin J.M., Beeh K.M., Clemens A. et al. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and pulmonary function in Шпагина Л.А. и др.Дифференцированная терапия различных фенотипов хронической обструктивной болезни легких the moRnING).Int. J. Chron. Obstruct. Pulm. Dis.2016; 11: 1425–134.
(check this in PDF content)
5
Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 1153–1162. DOI:http:// dx.doi.org/10.1016/j.rmed.2014.05.013.
(check this in PDF content)
6
Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016; 47 (2): 410–419. DOI: 10.1183/13993003.01359-2015.
(check this in PDF content)
7
Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118–125.
(check this in PDF content)
8
Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957–963. DOI:10.1136/thoraxjnl-2011-201518.
(check this in PDF content)
9
Miravitlles M., Soler-Cataluna J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Eur. Respir. J. 2013; 41 (6): 1252–1256.
(check this in PDF content)
10
Rennard S.I., Calverley P.M., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18.
(check this in PDF content)
11
Чучалин А.Г., Шпагина Л.А., Васильева О.С. и др. Профессиональная хроническая обструктивная болезнь легких. Профессиональные заболевания органов дыхания: Национальное руководство. M.: ГЭОТАР; 2015: 293–338.
(check this in PDF content)
12
Rodríguez E., Ferrer J., Zock J.P. et al. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One.2014; 9 (2): e88426.
(check this in PDF content)
13
Brüske I., Thiering E., Heinrich J. et al. Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One. 2013; 8 (11): e80977.
(check this in PDF content)
14
Шпагина Л.А., Воевода М.И., Котова О.С. и др. Профессиональная хроническая обструктивная болезнь легких с позиций молекулярно-генетических исследований. Бюллетень физиологии и патологии дыхания. 2013; (49): 8–15.
(check this in PDF content)
15
Miller J., Edwards L.D., AgustíA. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107 (9): 1376–1384.
(check this in PDF content)
16
Shrikrishna D., Astin R., Kemp P.R., Hopkinson N.S. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin. Sci. (Lond). 2012; 123 (8): 487–498.
(check this in PDF content)
17
Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC).J. Hypertens. 2013; 31 (7): 1281–1357.
(check this in PDF content)
18
Miller M.R., Hankinson J., Brusasco V. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338.
(check this in PDF content)
19
Rossi A., Zanardi E., Poletti V., Cazzola M. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1383–1392.
(check this in PDF content)
20
Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013; 10 (4): 511–522.
(check this in PDF content)